Syndax Pharmaceuticals, Inc. (SNDX)
20.11
+0.82
(+4.25%)
USD |
NASDAQ |
Sep 01, 16:00
20.11
0.00 (0.00%)
After-Hours: 17:26
Syndax Pharmaceuticals Total Long Term Debt (Quarterly) : 588.88M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 588.88M |
| March 31, 2026 | 344.87M |
| December 31, 2025 | 344.96M |
| September 30, 2025 | 345.10M |
| June 30, 2025 | 345.18M |
| March 31, 2025 | 345.25M |
| December 31, 2024 | 345.27M |
| September 30, 2024 | 0.012M |
| June 30, 2024 | 0.149M |
| March 31, 2024 | 0.346M |
| December 31, 2023 | 0.60M |
| September 30, 2023 | 0.875M |
| June 30, 2023 | 1.142M |
| March 31, 2023 | 0.605M |
| December 31, 2022 | 0.727M |
| September 30, 2022 | 0.786M |
| June 30, 2022 | 20.79M |
| March 31, 2022 | 20.69M |
| December 31, 2021 | 20.61M |
| September 30, 2021 | 21.28M |
| June 30, 2021 | 20.38M |
| March 31, 2021 | 20.29M |
| December 31, 2020 | 20.22M |
| September 30, 2020 | 20.18M |
| Date | Value |
|---|---|
| June 30, 2020 | 20.14M |
| March 31, 2020 | 20.10M |
| December 31, 2019 | 0.419M |
| September 30, 2019 | 0.525M |
| June 30, 2019 | 0.725M |
| March 31, 2019 | 0.83M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| September 30, 2014 | 4.87M |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 1.489M |
| March 31, 2013 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | 3.925M |
| Kura Oncology, Inc. | 23.16M |
| ACADIA Pharmaceuticals, Inc. | 59.55M |
| Alnylam Pharmaceuticals, Inc. | 2.942B |
| Anika Therapeutics, Inc. | 23.32M |